TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Risk of HE episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HE-related hospitalizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma Control Test (ACT) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in peak oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative cTnT production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: arrhythmic death or resuscitated cardiac arrest
Endpoint domain: Mortality/survival
Primary endpoint: subjective craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BOLD activations of brain regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average annual savings
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: median percent time with nocturnal pH lower than 4.0
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: per capita Pap test rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thyroid Volume (ThV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: net parotid count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of relevant symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Corneal deswelling rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: performance improvement in swimming
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6 Minute Walk Test distance (6 MWTd)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional capacity (FC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normal EF domain score at endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in intracorporeal suturing skill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood loss collected on swabs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood loss into suction drains in the first 24 h after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinically significant device pocket haematoma
Endpoint domain: Adverse events/effects
Primary endpoint: clinically basic recovery rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean direct health care costs per person
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Delta[Hgb]
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Future risk of developing gynecologic cancer
Endpoint domain: Mortality/survival
Primary endpoint: Statistically significant improvements in TS-VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responder analyses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of blood loss during operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Grade 2-4 acute toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Assessment of Spondyloarthritis International Society 20/40 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No radiographic progression (mSASSS change from Baseline < 2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Paresthesia in the scar region
Endpoint domain: Adverse events/effects
Primary endpoint: GHQ-12 score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: proportion of women with high BDI scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: AQLQ total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: emotion score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: thrombomodulin-positive cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percent improvement in NIH Stroke Scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of pre-diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Uncontrolled diabetes prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Impaired HbA1c prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary NTX levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum ALP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postoperative relaxation levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain medication requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abstinence rates at week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall retention rate at week 12
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement in memory impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: D-dimer changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t-PA antigen levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean crying time per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mother-infant interaction behaviors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postoperative opioid usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic pain at three months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conjunctival bacterial colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Treatment failure (TF) rate within 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment intensification rate within 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality rate within 3 months
Endpoint domain: Mortality/survival
Primary endpoint: number of bladder contractions not leading to a void
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Fasting Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Physical activity levels during school recess
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival rates from OOH-CA
Endpoint domain: Mortality/survival
Primary endpoint: successful intraocular pressure control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: early postoperative hypotony
Endpoint domain: Adverse events/effects
Primary endpoint: Perception of intestinal distentions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: avoidance of any allogeneic blood product
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Accuracy of MRA in mapping perforator arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean difference in breast reconstruction volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of immune response genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: laryngeal view improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in primary enamel surface lesion depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in root surface lesion depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in PASI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction in state anxiety (STAI-1)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: FFI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plantar flexion range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of medication-related hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Costs for medication-related hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Postoperative Nausea and Vomiting (PONV) incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of disability progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI-related measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visceral adipose tissue (VAT) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Limb fat reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cerebral and systemic venous oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Temperature differential
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stinging sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: softness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: skin comfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: cessation of spasms rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Allergen-induced nasal congestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leukotriene B4 levels in nasal-rinse fluids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Synthesis of leukotriene B4 in whole blood ex vivo
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patient participation in care decision-making
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in daily UI episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Engagement in treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Understanding of treatment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Acquisition of new skills
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: adequate visit adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: adequate medication adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: incidence of meatal stenosis
Endpoint domain: Adverse events/effects
Primary endpoint: response latencies in Moral Personal dilemmas
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Heartburn frequency and severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endoscopic oesophagitis healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Stroke Scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: breast cancer-specific mortality
Endpoint domain: Mortality/survival
Primary endpoint: Bleeding volume of caesarean section
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of obstetric forceps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Effectiveness of combined spinal-epidural analgesia (CSEA) for analgesia labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of hyperbilirubinemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver and biliary outcomes
Primary endpoint: Incidence of liver failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver and biliary outcomes
Primary endpoint: Lf concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: progression of sepsis during hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Patient understanding of medications
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-reported medication error
Endpoint domain: Adverse events/effects
Primary endpoint: Drain output reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of HIV genital shedding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of HSV-2 genital shedding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: score of neurological defection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: incidence rate of disability
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma concentrations of lidocaine and MEGX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Diabetic Retinopathy Severity Scale (DRSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best-corrected visual acuity (BCVA) letter score gain of 15 letters or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of macular edema (central foveal thickness of 250 μm or less)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oral hygiene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AD severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall performance of pull-ups vs. diapers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Night vision test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Temperature values in the masseter region
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-treatment pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle sensitivity values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention rate at 12 months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: plasma sFLT1 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: placental growth factor concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: free vascular endothelial growth factor concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: treatment control perceptions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: social quality of life
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Concentrations of ECP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UPDRS 3 improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Effectiveness of R20 method in tattoo removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete remission rate of neck lymph node
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: 6-month seizure-freedom rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: retention rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: incidences of treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Cytokine IL-6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cytokine IL-8 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cytokine responses to schistosome antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IgG levels to SWA and SEA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: level of energy after sleep deprivation
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Urine excretion of albumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urine excretion of alpha1 microglobulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Median time to maximum serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to maximum tissue concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of sensitizer in tumor/tumor bed tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cortical GM volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total GM volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: RFS
Endpoint domain: Mortality/survival
Primary endpoint: IFFS
Endpoint domain: Mortality/survival
Primary endpoint: proportion of participants with depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: suppression of hunger
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: energy intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Access site complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Vessel patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: overall reduction in the risk of death
Endpoint domain: Mortality/survival
Primary endpoint: Improvement of OAB symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of vibegron
Endpoint domain: Adverse events/effects
Primary endpoint: Fasting reactive hyperemia index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mean number of GFs per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients without GFs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone resorption markers (urinary CTx/Cr, Pyr/Cr, D-Pyr/Cr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ionized Ca levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Chronic allograft nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Sensitivity of CMR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity of MPS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Positive predictive value (PPV) of CMR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Positive predictive value (PPV) of MPS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: patient-reported pain at pessary removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of selective bile duct cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: HIV drug resistance mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: NRS anxiety scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Readiness for discharge
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mean peak plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean relative bioavailability (AUC(0‐168))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: renin activity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: arginine vasopressin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: atrial natriuretic peptide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: reduce patient symptom burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antioxidant enzymes activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammatory markers (TNF‐α)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes